BioSpecifics Technologies Corp. is a biopharmaceutical company that is the originator of collagenase-based therapies with injectable collagenase for twelve clinical indications to date. Injectable collagenase (collagenase clostridium histolyticum or CCH) is marketed as XIAFLEXÂŽ in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEXÂŽ is also commercialized in Japan, Europe, Canada and Australia for Dupuytrenâs contracture and for Peyronie's disease in Canada, Europe and Australia. Source
No articles found.
Global Cancer Technology was formed to acquire a portfolio of various medical lice...
Global Cancer Technology was formed to acquire ...
Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing...
Sol-Gel is a clinical-stage specialty pharmaceu...
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients w...
At ACADIA (NASDAQ: ACAD), we share a passion fo...
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
KalVista is a pharmaceutical company focused on the discovery, development and com...
KalVista is a pharmaceutical company focused on...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering n...
Revance Therapeutics is a Silicon Valley-based ...
Join the National Investor Network and get the latest information with your interests in mind.